Tissium, a medtech company spun out of a PhD project, has developed a polymer that can repair severed nerves without sutures. The approach, which the firm claims simplifies a delicate procedure, just secured €60 million in new funding to break into the U.S. operating room.
The Series B round was led by a syndicate of investors including Sectoral Asset Management and European Innovation Council Fund, with participation from existing backers. The fresh capital will be used to support clinical trials and regulatory approval in the United States, a critical step for commercial expansion.
Current standard of care for nerve repair involves microsurgical suturing, a technique that has remained largely unchanged for decades. Tissium's polymer offers a sutureless alternative, which could reduce procedure time and improve outcomes. The global market for nerve repair and regeneration is estimated at over $7 billion, according to firm's internal data.
If successful in trials, this technology could shift surgical practice across multiple specialties beyond nerve repair, including vascular grafts and soft tissue reconstruction. The round signals growing investor appetite for biomaterials that replace traditional mechanical methods.
The company was founded by a PhD student who developed the polymer as part of their doctoral research, though specific founder details were not provided in the report.